Warby Parker
WRBY
$26.08
+22.50%
Warby Parker Inc. is a vertically integrated, direct-to-consumer eyewear brand that designs, manufactures, and sells prescription glasses, sunglasses, contact lenses, and related accessories, while also delivering optical exams and vision care services through a growing network of physical retail locations and its e-commerce and mobile platforms. The company operates in the Consumer Cyclical sector within Specialty Retail, positioning itself as a design-led, technology-enabled challenger to legacy optical incumbents such as EssilorLuxottica-owned retail chains, differentiated by its transparent pricing, in-house brand equity, and mission-driven 'buy a pair, give a pair' social enterprise model. The current investor narrative centers on the company's transition from a high-growth, cash-burning disruptor to a profitability story, with recent quarters showing positive net income, gross margin expansion toward the high-50s, and disciplined cost control, even as revenue growth decelerates to high-single digits. Debate now hinges on whether store expansion, contact lens attach rates, and insurance/vision-care partnerships can reaccelerate top-line growth enough to justify a premium multiple, particularly after the stock's sharp recent pullback and elevated short interest suggest growing skepticism about near-term demand and margin durability.…
WRBY
Warby Parker
$26.08
Investment Opinion: Should I buy WRBY Today?
Rating: Hold with a constructive bias. The core thesis is that WRBY has genuinely crossed into profitability — Q2 2026 net income of $4.64 million versus a $1.75 million loss a year earlier, gross margin up ~500bps to 57.94%, and operating income swinging from -$4.53 million to +$3.17 million — but the 35.69x forward PE already discounts much of that inflection while revenue growth has decelerated to 9.81%, leaving the risk/reward roughly balanced at $21.94. The analyst consensus of 'buy' (10 Buy, 3 Hold, 0 Sell, mean 1.62) with a $31.00 average target implying 41.3% upside anchors the constructive side, but the wide gap to a stock down 18.83% in a month suggests those targets are stale rather than predictive.
Supporting evidence for holding rather than selling: the balance sheet is self-funding with $292.67 million of cash, a 2.35 current ratio, and 0.634 debt-to-equity, plus $21.75 million of trailing free cash flow against $22.86 million of quarterly capex. Profitability is trending in the right direction across the last four quarters — operating margin of -3.23% in Q4 2025, +0.69% in Q1 2026, and +1.34% in Q2 2026 — and EBITDA nearly doubled year-over-year to $19.32 million. Valuation has de-rated hard from a 39.4x PS in Q4 2021 to 3.07x today, near the floor of its historical band, which limits further multiple compression. Against that, the 49.13x EV/EBITDA and 24.13x PCF are rich for a high-single-digit grower, ROE of 0.45% and ROA of -1.02% show capital returns remain poor, and the consensus FY EPS of $1.38 requires a dramatic step-up from trailing EPS of $0.0006.
The biggest risks that could invalidate even a Hold are: (1) a Q3 revenue miss that forces analysts to cut the $1.38 EPS estimate and the $31.00 target, removing the multiple's support; (2) margin flow-through stalling, since a 1.97% net margin leaves almost no buffer; and (3) continued relative weakness — -23.03% versus SPY over three months with a beta of 1.952 — accelerating a de-rating toward the $14.96 52-week low. This Hold would upgrade to Buy on evidence of revenue reaccelerating above ~12% with gross margin holding near 58%, or on a pullback toward $18–$19 that restores a margin of safety; it would downgrade to Sell if growth falls below 7% or if gross margin slips back under 55%. On balance the stock looks fairly valued to modestly undervalued versus its own history but expensive versus current fundamentals — a show-me story rather than a compelling entry.
Sign up to view all
WRBY 12-Month Price Forecast
The forward view is genuinely two-sided: the margin-driven earnings inflection is real and self-funded, with gross margin at 57.94%, positive operating income, $292.67 million of cash, and $21.75 million of trailing free cash flow, yet revenue growth of 9.81% is too slow to comfortably support a 35.69x forward PE and 49.13x EV/EBITDA without further margin delivery. The analyst consensus is firmly bullish at a 1.62 mean with zero Sells and a $31.00 target, but the 41.3% implied upside alongside a -18.83% one-month decline and no recent upgrades signals stale models vulnerable to downward revision. Valuation has already de-rated from a 39.4x PS in Q4 2021 to 3.07x, so much speculative premium is gone, but ROE of 0.45% and ROA of -1.02% show the business still earns poor returns on capital. I would upgrade to bullish on a Q3 print showing revenue growth above 12% with gross margin at or above 58%, and downgrade to bearish if growth falls below 7% or gross margin drops under 55%, either of which would likely send the stock toward the $14.96 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Warby Parker's 12-month outlook, with a consensus price target around $31.00 and implied upside of +18.9% versus the current price.
Average Target
$31.00
13 analysts
Implied Upside
+18.9%
vs. current price
Analyst Count
13
covering this stock
Price Range
$25 - $35
Analyst target range
Coverage is reasonably robust with 12 analysts, and the distribution is decisively bullish: 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings, yielding a consensus recommendation of 'buy' and a recommendation mean of 1.62 (where 1.0 is a strong buy). The average target price of $31.00 implies roughly 41.3% upside from the current $21.94, a wide gap that suggests analysts have not yet marked their models down to the recent price action and may be anchored to earlier, more optimistic assumptions. The consensus leans clearly bullish, but the sharp disconnect between the +41% implied upside and the stock's -18.83% one-month decline is a warning sign that targets may be stale and vulnerable to downward revisions if the next earnings print disappoints. The target range spans $25.00 to $35.00, a spread of about 40% of the midpoint, which signals meaningful uncertainty rather than tight conviction; the high target of $35.00 likely assumes multiple expansion on accelerating store productivity, contact lens attach, and margin flow-through toward the high-50s gross margin, while the low target of $25.00—still 14% above the current price—prices in slower growth, competitive pressure from incumbents, and limited margin upside. Institutional ratings show a stable-to-cautious pattern: Citizens and BTIG maintain Market Outperform/Buy, Telsey and Piper Sandler remain Outperform/Overweight, but UBS, Citigroup, and Stifel sit at Neutral/Hold, and there have been no recent upgrades—only reiterations—suggesting analysts are in a holding pattern awaiting evidence of a growth reacceleration before turning more constructive.
Drowning in data?
Find the real signal!
Bulls vs Bears: WRBY Investment Factors
The bear case currently has stronger near-term evidence: the stock has broken down 18.83% in a month against a flat market, revenue growth has decelerated to 9.81%, and the 35.69x forward PE prices in an earnings inflection that has not yet been demonstrated at scale. The bull case rests on genuinely improving fundamentals — gross margin up ~500bps to 57.94%, operating income turning positive, and a self-funding balance sheet — plus a valuation that has compressed to the bottom of its historical range and an analyst consensus with zero Sells and a $31.00 average target. The single most important tension is whether the margin-driven earnings inflection can be delivered on high-single-digit revenue growth, or whether slowing top-line momentum forces analysts to cut the $1.38 FY EPS estimate and the $31.00 target, which would remove the primary support for the multiple. Until the next earnings print resolves that question, the risk/reward is balanced but the tape favors caution.
Bullish
- Gross margin expanded ~500bps YoY: Q2 2026 gross margin reached 57.94% versus 52.97% in Q2 2025, a roughly 500-basis-point improvement driven by pricing power, lower discounting, and supply-chain leverage. This is the clearest evidence that the DTC model can generate retail-quality margins as scale builds, and it is the single most important input to the earnings inflection the forward multiple assumes.
- Profitability inflection is real: Q2 2026 net income of $4.64 million (1.97% net margin) compares with a $1.75 million loss a year earlier, and operating income swung from -$4.53 million to +$3.17 million. EBITDA nearly doubled to $19.32 million (8.20% margin) from $9.95 million, showing operating leverage is now flowing through even as revenue growth decelerates to 9.81%.
- Analyst consensus firmly bullish: 10 of 12 covering analysts rate the stock Buy with zero Sells, a recommendation mean of 1.62, and an average target of $31.00 implying 41.3% upside from $21.94. Even the lowest target of $25.00 sits 14% above the current price, meaning the entire published range is above the market.
- Valuation de-rated to historical floor: The PS ratio has compressed from 39.4x in Q4 2021 and 25.2x in Q1 2022 to 3.07x today, placing the stock near the bottom of its own historical band. Much of the speculative premium has been wrung out, so further downside from multiple compression is more limited than at any prior point in its public history.
Bearish
- Revenue growth decelerating to high-single digits: Q2 2026 revenue of $235.51 million grew 9.81% year-over-year, down from the ~13% implied by Q1 2026's $242.45 million versus $223.78 million. A 35.69x forward PE on a high-single-digit grower leaves little room for further deceleration before the multiple looks unjustifiable.
- Severe recent underperformance and momentum break: The stock is down 18.83% over one month and 25.04% over three months, versus SPY at -1.99% and -2.01%, producing relative strength of -16.84% and -23.03%. The most recent session alone fell 8.05% on elevated volume of 4.38 million shares, signaling institutional distribution rather than noise.
- Analyst targets look stale: The 41.3% gap between the $31.00 average target and the $21.94 price is unusually wide and coincides with a sharp one-month decline, suggesting models have not been marked down. There have been no recent upgrades, only reiterations, and UBS, Citigroup, and Stifel already sit at Neutral/Hold, leaving room for downward target revisions.
- Revenue concentrated in core eyewear: Eyewear products generated $191.76 million of the quarter's revenue, meaning the business remains heavily dependent on core glasses rather than higher-growth contact lenses or services. This limits the growth optionality investors would need to underwrite a reacceleration story.
WRBY Technical Analysis
WRBY is in a choppy, range-bound consolidation rather than a clean trend, with the stock up 10.98% over the past year but sitting at $21.94, which is only about 44.9% of its 52-week range of $14.96 to $31.00. That positioning—roughly mid-to-lower in the annual band despite a positive 1-year return—signals that the stock has given back most of its earlier gains and is closer to a value/mean-reversion zone than a momentum breakout, though it remains well above the 52-week low, so it is not a falling knife. The recent tape is decisively weak: the stock is down 18.83% over the past month and 25.04% over three months, a sharp deceleration versus the +10.98% 1-year gain, and the most recent session saw an 8.05% single-day drop from $23.86 to $21.94 on elevated volume of 4.38 million shares. This divergence—positive long-term but sharply negative short-term—points to a trend reversal or at minimum a violent mean-reversion move, and the 1-month relative strength of -16.84% versus SPY (which fell only 1.99%) confirms severe idiosyncratic underperformance rather than broad market weakness. Key support sits at the 52-week low of $14.96, with the recent $21.94 close now testing the lower half of the range; resistance is the 52-week high of $31.00, and a reclaim of the $26–$28 area (the September–October consolidation zone) would be needed to neutralize the bearish momentum. A beta of 1.952 means the stock is roughly 95% more volatile than the market, so position sizing should account for roughly double the market's drawdown risk, and the -40.21% max drawdown underscores how violently this name can correct; a breakdown below $21 would likely target the $15 area, while a breakout above $31 would signal a new leg higher.
Beta
1.95
1.95x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$15-$31
Price range past year
Annual Return
+36.9%
Cumulative gain past year
| Period | WRBY Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | -5.9% |
| 3m | -1.4% | -5.2% |
| 6m | -11.7% | -0.6% |
| 1y | +36.9% | +8.2% |
| ytd | +15.3% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRBY Fundamental Analysis
Revenue is growing but decelerating: Q2 2026 revenue was $235.51 million, up 9.81% year-over-year, a modest pace for a growth-oriented retailer and a step down from the ~13% growth implied by Q1 2026's $242.45 million versus Q1 2025's $223.78 million. The multi-quarter trend shows sequential revenue of $211.97M (Q4 2025), $242.45M (Q1 2026), and $235.51M (Q2 2026), with the year-over-year comparison against Q2 2025's $214.48M confirming high-single-digit expansion rather than acceleration. Eyewear products remain the dominant revenue driver at $191.76 million, meaning the business is still heavily concentrated in core glasses rather than diversified into higher-growth contact lenses or services, which limits the growth optionality investors might otherwise underwrite. Profitability has inflected positively: Q2 2026 net income was $4.64 million (a 1.97% net margin) versus a net loss of $1.75 million in Q2 2025, and gross margin expanded to 57.94% from 52.97% a year earlier, a roughly 500-basis-point improvement that reflects pricing power, lower discounting, and supply-chain leverage. Operating income turned positive at $3.17 million (1.34% operating margin) versus -$4.53 million a year ago, and EBITDA rose to $19.32 million (8.20% margin) from $9.95 million, showing the company is now generating positive operating leverage even as revenue growth slows. The balance sheet is solid: cash of $292.67 million against a debt-to-equity ratio of 0.634 and a current ratio of 2.35 provides ample liquidity, while trailing free cash flow of $21.75 million and Q2 operating cash flow of $29.62 million (against $22.86 million of capex) show the business is self-funding. However, ROE of just 0.45% and ROA of -1.02% remain weak, and stock-based compensation of $9.90 million in Q2 is a meaningful non-cash drag on true economic earnings, meaning the company's cash generation is real but modest relative to its $2.67 billion market cap.
Quarterly Revenue
$235511000.0B
2026-06
Revenue YoY Growth
+9.8%
YoY Comparison
Gross Margin
57.9%
Latest Quarter
Free Cash Flow
$21745999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRBY Overvalued?
Because trailing net income is barely positive (EPS of $0.0006), the trailing PE of 1,626x is economically meaningless, so the appropriate primary metric is the forward PE of 35.69x, which reflects the market's expectation that earnings will normalize toward the consensus FY estimate of $1.38 per share. The gap between the meaningless trailing multiple and the 35.69x forward multiple implies the market is pricing in a sharp earnings inflection over the next twelve months, and the PS ratio of 3.07x and EV/Sales of 2.93x provide a cleaner read on the revenue-based valuation. Peer comparison is constrained because no explicit industry-average multiples were provided in the valuation dataset, but a 3.07x PS ratio for a high-single-digit-growth specialty retailer with a 54% gross margin and near-zero net margin is a premium valuation that requires either reaccelerating growth or sustained margin expansion to justify; the 49.13x EV/EBITDA is rich relative to mature retail peers and signals the market is capitalizing future margin improvement rather than current cash flow. Historically, WRBY's PS ratio has compressed dramatically from 39.4x in Q4 2021 and 25.2x in Q1 2022 down to 3.07x today, placing the stock near the bottom of its own historical valuation band—a de-rating that reflects the transition from hyper-growth story to profitability-focused retailer. That compression cuts both ways: it suggests much of the speculative premium has been wrung out, but it also means the market is no longer willing to pay for growth optionality, so further multiple expansion likely requires demonstrated earnings delivery rather than narrative alone.
PE
1626.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 151x~190x
vs. Industry Avg
29.4x
Industry PE ~29.4x*
EV/EBITDA
49.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the mismatch between a 35.69x forward PE and 9.81% revenue growth. The consensus FY EPS estimate of $1.38 implies a dramatic step-up from trailing EPS of $0.0006, so any shortfall in margin flow-through would compress the multiple sharply; Q2 net margin was only 1.97% and operating margin 1.34%, leaving thin buffers. Revenue is concentrated in eyewear products at $191.76 million of the quarter's total, limiting diversification into contact lenses and services, and stock-based compensation of $9.90 million in Q2 dilutes true economic earnings. ROE of 0.45% and ROA of -1.02% confirm the business still earns poor returns on capital despite the profitability inflection. Market and competitive risks are amplified by a beta of 1.952, meaning the stock carries roughly double the market's volatility and is highly sensitive to any risk-off rotation away from unprofitable-growth-turned-margin stories. The 3.07x PS and 49.13x EV/EBITDA multiples are rich for a high-single-digit grower facing EssilorLuxottica-backed incumbents with far greater scale and vertical integration, and the stock's -23.03% three-month relative strength versus SPY shows the market is already rotating away. Elevated short interest, reflected in a 5.88 short ratio, adds squeeze potential in both directions and increases the violence of moves around earnings. The worst-case scenario is a Q3 print that misses revenue expectations, forces analysts to cut the $1.38 EPS estimate and the $31.00 target, and triggers a de-rating toward the low end of the historical PS band. In that chain, the stock would retest the 52-week low of $14.96, a decline of roughly 32% from the current $21.94, consistent with the -40.21% max drawdown already experienced; a break below the $21 support level would likely accelerate toward the $15 area.
FAQ
The most severe risk is earnings-delivery risk: the 35.69x forward PE depends on consensus EPS of $1.38 versus trailing EPS of $0.0006, and with a Q2 net margin of only 1.97% and operating margin of 1.34%, there is almost no buffer if margin flow-through disappoints. Second is growth deceleration — revenue grew 9.81% YoY in Q2 2026, and a print below 7% would likely trigger estimate cuts and a de-rating toward the $14.96 52-week low, roughly 32% below the current price. Third is competitive and concentration risk, since eyewear products generated $191.76 million of quarterly revenue and Warby Parker competes against EssilorLuxottica-backed incumbents with far greater scale and vertical integration. Fourth is market-structure risk: beta of 1.952 means roughly double the market's volatility, the stock has already suffered a -40.21% max drawdown, and a 5.88 short ratio amplifies moves around earnings. Ranked by severity, earnings delivery and growth deceleration come first, competitive pressure second, and volatility/short-interest dynamics third.
The scenario framework assigns a 50% probability to the base case of $25-$31, a 25% probability to the bull case of $31-$35, and a 25% probability to the bear case of $14.96-$25. The base case assumes revenue growth of roughly 9-11%, gross margin near 57-58%, and full-year EPS in line with the $1.38 consensus, letting the stock grind back toward the $31.00 analyst average without requiring multiple expansion. The bull case requires revenue reaccelerating above 12% with gross margin at or above 58%, lifting the stock through the $31.00 52-week high toward the $35.00 analyst high target. The bear case is a Q3 revenue miss or margin slip that forces EPS and target cuts, compressing the multiple and retesting the $14.96 low. The base case is most likely because it requires only continuation of the current trajectory rather than acceleration, but the wide $25-$35 analyst range and the 41.3% gap between target and price signal genuine uncertainty about which path unfolds.
The answer depends heavily on which lens is used, because trailing earnings are essentially nil (EPS of $0.0006, trailing PE of 1,626x) and therefore meaningless. On forward numbers the stock trades at 35.69x the $1.38 consensus EPS and 49.13x EV/EBITDA, which is a premium multiple for a high-single-digit grower and implies the market is already capitalizing a successful margin inflection. On sales, the 3.07x PS and 2.93x EV/Sales are far below the 39.4x PS seen in Q4 2021 and 25.2x in Q1 2022, placing the stock near the floor of its own historical band and suggesting most speculative premium has been wrung out. The 7.27x price-to-book and 24.13x price-to-cash-flow sit between those extremes. Net, WRBY looks fairly valued to modestly undervalued versus its own history but expensive versus current fundamentals — the market is paying today for earnings it expects tomorrow, so the valuation is only justified if gross margin holds near 58% and operating leverage continues.
From a risk/reward standpoint WRBY is balanced rather than compelling at $21.94. The upside case is anchored by a $31.00 average analyst target implying 41.3% upside, a consensus of 10 Buy versus 0 Sell, and a valuation that has compressed to 3.07x PS from 39.4x in Q4 2021, while the business has genuinely turned profitable with Q2 2026 net income of $4.64 million and gross margin of 57.94%. The downside case is that the 35.69x forward PE rests on a $1.38 consensus EPS that is a dramatic step-up from trailing EPS of $0.0006, and revenue growth of just 9.81% offers little cushion if margins stall. The stock's -18.83% one-month decline, -23.03% three-month relative strength versus SPY, and beta of 1.952 show how violently it can move against holders. It is a reasonable buy for patient investors with a 2-3 year horizon who want a margin-inflection story at a de-rated multiple, and a poor buy for anyone expecting near-term momentum or needing the analyst target to be validated quickly.
WRBY is better suited to a long-term hold than to short-term trading, though position sizing must respect its volatility. The stock pays no dividend (payout ratio of 0), so total return depends entirely on earnings growth and multiple re-rating, which is a multi-year process as store expansion, contact lens attach, and insurance partnerships mature. Beta of 1.952, a -40.21% max drawdown, and an 8.05% single-day drop on 4.38 million shares on the most recent session make it a poor vehicle for traders without strict risk controls, and the 5.88 short ratio means earnings dates carry outsized gap risk. Earnings visibility is improving — four consecutive quarters show operating margin moving from -3.23% in Q4 2025 to +0.69% in Q1 2026 and +1.34% in Q2 2026 — but the 35.69x forward multiple leaves little room for error. A minimum holding period of 18-24 months, sized at roughly half a normal position given the beta, is appropriate for investors underwriting the margin-inflection thesis.